FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2773047103> ?p ?o ?g. }

• W2773047103 endingPage "765" @default.
• W2773047103 startingPage "758" @default.
• W2773047103 abstract "Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the MET tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic ASPS.Eligible patients with reference pathology-confirmed ASPS received oral crizotinib 250 mg bd. By assessing the presence or absence of a TFE3 rearrangement, patients were attributed to MET+ and MET- sub-cohorts. The primary end point was the objective response rate (ORR) according to local investigator. Secondary end points included duration of response, disease control rate (DCR), progression-free survival (PFS), progression-free rate, overall survival (OS) and safety.Among 53 consenting patients, all had a centrally confirmed ASPS and 48 were treated. A total of 45 were eligible, treated and assessable. Among 40 MET+ patients, 1 achieved a confirmed partial response (PR) that lasted 215 days and 35 had stable disease (SD) as best response (ORR: 2.5%, 95% CI 0.6% to 80.6%). Further efficacy end points in MET+ cases were DCR: 90.0% (95% CI 76.3% to 97.2%), 1-year PFS rate: 37.5% (95% CI 22.9% to 52.1%) and 1-year OS rate: 97.4% (95% CI 82.8% to 99.6%). Among 4 MET- patients, 1 achieved a PR that lasted 801 days and 3 had SD (ORR: 25.0%, 95% CI 0.6% to 80.6%) for a DCR of 100% (95% CI 39.8% to 100.0%). The 1-year PFS rate in MET- cases was 50% (95% CI 5.8% to 84.5%) and the 1-year OS rate was 75% (95% CI 12.8% to 96.1%). One patient with unknown MET status due to technical failure achieved SD but stopped treatment due to progression after 17 cycles. The most common crizotinib-related adverse events were nausea [34/48 (70.8%)], vomiting [22/48 (45.8%)], blurred vision [22/48 (45.8%)], diarrhoea (20/48 (41.7%)] and fatigue [19/48 (39.6%)].According to European Organization for Research and Treatment of Cancer (EORTC) efficacy criteria for soft tissue sarcoma, our study demonstrated that crizotinib has activity in TFE3 rearranged ASPS MET+ patients.EORTC 90101, NCT01524926." @default.
• W2773047103 created "2017-12-22" @default.
• W2773047103 creator A5000472375 @default.
• W2773047103 creator A5014078052 @default.
• W2773047103 creator A5015197719 @default.
• W2773047103 creator A5020934507 @default.
• W2773047103 creator A5021550191 @default.
• W2773047103 creator A5025935523 @default.
• W2773047103 creator A5027716206 @default.
• W2773047103 creator A5031540987 @default.
• W2773047103 creator A5038603211 @default.
• W2773047103 creator A5042202815 @default.
• W2773047103 creator A5042984084 @default.
• W2773047103 creator A5048170384 @default.
• W2773047103 creator A5055163903 @default.
• W2773047103 creator A5055506828 @default.
• W2773047103 creator A5060949051 @default.
• W2773047103 creator A5060954086 @default.
• W2773047103 creator A5061157288 @default.
• W2773047103 creator A5071545176 @default.
• W2773047103 creator A5074162105 @default.
• W2773047103 creator A5074975947 @default.
• W2773047103 creator A5075101700 @default.
• W2773047103 creator A5076043217 @default.
• W2773047103 creator A5080693514 @default.
• W2773047103 creator A5080808621 @default.
• W2773047103 creator A5082282434 @default.
• W2773047103 creator A5086102127 @default.
• W2773047103 date "2018-03-01" @default.
• W2773047103 modified "2023-10-14" @default.
• W2773047103 title "Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’" @default.
• W2773047103 cites W1966228869 @default.
• W2773047103 cites W1970261657 @default.
• W2773047103 cites W1987717836 @default.
• W2773047103 cites W2011352995 @default.
• W2773047103 cites W2012921981 @default.
• W2773047103 cites W2031044452 @default.
• W2773047103 cites W2046701234 @default.
• W2773047103 cites W2057195209 @default.
• W2773047103 cites W2101776780 @default.
• W2773047103 cites W2111842868 @default.
• W2773047103 cites W2126890359 @default.
• W2773047103 cites W2136344041 @default.
• W2773047103 cites W2146355396 @default.
• W2773047103 cites W2169500410 @default.
• W2773047103 cites W2259955047 @default.
• W2773047103 cites W298677108 @default.
• W2773047103 doi "https://doi.org/10.1093/annonc/mdx774" @default.
• W2773047103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29216400" @default.
• W2773047103 hasPublicationYear "2018" @default.
• W2773047103 type Work @default.
• W2773047103 sameAs 2773047103 @default.
• W2773047103 citedByCount "60" @default.
• W2773047103 countsByYear W27730471032018 @default.
• W2773047103 countsByYear W27730471032019 @default.
• W2773047103 countsByYear W27730471032020 @default.
• W2773047103 countsByYear W27730471032021 @default.
• W2773047103 countsByYear W27730471032022 @default.
• W2773047103 countsByYear W27730471032023 @default.
• W2773047103 crossrefType "journal-article" @default.
• W2773047103 hasAuthorship W2773047103A5000472375 @default.
• W2773047103 hasAuthorship W2773047103A5014078052 @default.
• W2773047103 hasAuthorship W2773047103A5015197719 @default.
• W2773047103 hasAuthorship W2773047103A5020934507 @default.
• W2773047103 hasAuthorship W2773047103A5021550191 @default.
• W2773047103 hasAuthorship W2773047103A5025935523 @default.
• W2773047103 hasAuthorship W2773047103A5027716206 @default.
• W2773047103 hasAuthorship W2773047103A5031540987 @default.
• W2773047103 hasAuthorship W2773047103A5038603211 @default.
• W2773047103 hasAuthorship W2773047103A5042202815 @default.
• W2773047103 hasAuthorship W2773047103A5042984084 @default.
• W2773047103 hasAuthorship W2773047103A5048170384 @default.
• W2773047103 hasAuthorship W2773047103A5055163903 @default.
• W2773047103 hasAuthorship W2773047103A5055506828 @default.
• W2773047103 hasAuthorship W2773047103A5060949051 @default.
• W2773047103 hasAuthorship W2773047103A5060954086 @default.
• W2773047103 hasAuthorship W2773047103A5061157288 @default.
• W2773047103 hasAuthorship W2773047103A5071545176 @default.
• W2773047103 hasAuthorship W2773047103A5074162105 @default.
• W2773047103 hasAuthorship W2773047103A5074975947 @default.
• W2773047103 hasAuthorship W2773047103A5075101700 @default.
• W2773047103 hasAuthorship W2773047103A5076043217 @default.
• W2773047103 hasAuthorship W2773047103A5080693514 @default.
• W2773047103 hasAuthorship W2773047103A5080808621 @default.
• W2773047103 hasAuthorship W2773047103A5082282434 @default.
• W2773047103 hasAuthorship W2773047103A5086102127 @default.
• W2773047103 hasBestOaLocation W27730471031 @default.
• W2773047103 hasConcept C101762097 @default.
• W2773047103 hasConcept C104317684 @default.
• W2773047103 hasConcept C121608353 @default.
• W2773047103 hasConcept C126322002 @default.
• W2773047103 hasConcept C136948725 @default.
• W2773047103 hasConcept C141071460 @default.
• W2773047103 hasConcept C143998085 @default.
• W2773047103 hasConcept C150194340 @default.
• W2773047103 hasConcept C185592680 @default.
• W2773047103 hasConcept C203092338 @default.
• W2773047103 hasConcept C207103383 @default.

• next